Manufacturing & Quality

Accelerated conditions (40°C/75%RH for 6 months) provide preliminary stability data within approximately 6-9 months (including analysis time), supporting initial shelf-life claims while long-term data are collected. The Arrhenius equation can extrapolate degradation rates from accelerated to storage conditions for simple degradation pathways: ln(k) = ln(A) - Ea/RT (where k is rate constant, Ea is activation energy, R is gas constant, T is temperature). However, Arrhenius extrapolation has limitations for peptides: multiple degradation pathways with different activation energies may operate, phase transitions (lyophilised peptides may undergo glass transition at elevated temperatures, changing degradation kinetics), and aggregation pathways may not follow simple Arrhenius kinetics. ICH Q1E provides guidance on extrapolation of stability data for shelf-life estimation.

AAA procedure: (1) acid hydrolysis (6N HCl, 110°C, 18-24 hours — breaks all peptide bonds, but destroys Trp completely and partially degrades Cys, Met, Ser, Thr), (2) derivatisation (converting free amino acids to UV/fluorescent derivatives for detection — pre-column: OPA, FMOC, AQC, dansyl chloride; post-column: ninhydrin), (3) separation (RP-HPLC or ion-exchange chromatography), and (4) quantification (comparing peak areas to amino acid standards). Results: molar ratios of each amino acid compared to theoretical composition. AAA confirms overall composition but NOT sequence (Gly-Ala-Ser gives identical AAA results to Ser-Gly-Ala). For Trp quantification: alkaline hydrolysis (4M methanesulfonic acid, which preserves Trp) or spectrophotometric estimation is used. For Cys: performic acid oxidation (converting Cys to cysteic acid, which is stable to acid hydrolysis) is used before hydrolysis. AAA is also used for peptide content determination — quantifying the actual peptide mass per vial.

ICH Q2(R1) validation parameters: specificity (ability to measure the analyte in the presence of impurities, degradation products, and matrix components), linearity (proportional detector response across concentration range — r² >0.999 for quantitative methods), accuracy (closeness to true value — assessed by spiking studies, typically 98-102% recovery), precision (reproducibility: repeatability — same analyst, same day, RSD <1%; intermediate precision — different analysts/days/instruments, RSD <2%), range (validated concentration interval — typically 80-120% of target for assay methods, LOQ to 120% for impurity methods), detection limit (LOD — lowest detectable amount, typically signal-to-noise ≥3), quantitation limit (LOQ — lowest quantifiable amount with acceptable precision/accuracy, typically S/N ≥10), and robustness (deliberate variation of method parameters to assess sensitivity — e.g. ±2°C column temperature, ±0.1 pH buffer).

Aseptic processing for peptide products: drug substance and excipients are sterile-filtered (0.22μm membrane filter — peptides must be soluble and non-aggregating at filter concentration), containers and closures are separately sterilised (dry heat depyrogenation for glass at ≥250°C/≥30 min, gamma irradiation or autoclaving for rubber closures), and the sterile components are assembled in an ISO 5/Grade A cleanroom environment with ISO 7/Grade B background. Critical controls: environmental monitoring (viable and non-viable particle counts, settle plates, contact plates, personnel monitoring), aseptic technique (gowning, personnel qualification), and process simulation (media fill trials — filling containers with sterile growth medium instead of product, incubating, and checking for contamination — performed at least semi-annually, requiring <1 contaminated unit per 5000 filled). Aseptic processing has inherently higher contamination risk than terminal sterilisation, which is why media fill validation and environmental monitoring are essential.

Bacteriostatic water USP: water for injection containing 0.9% (w/v) benzyl alcohol as an antimicrobial preservative. Benzyl alcohol mechanism: disrupts bacterial cell membrane integrity, inhibiting growth of most common contaminants. Multi-dose vial usage: each withdrawal introduces potential contaminants from the needle, stopper, and environment — benzyl alcohol prevents their proliferation. The 28-day multi-use limit is based on preservative efficacy testing demonstrating adequate antimicrobial activity for this duration under normal use conditions. Contraindications: benzyl alcohol is contraindicated in neonates and premature infants (associated with gasping syndrome — metabolic acidosis, neurological deterioration, potentially fatal; due to immature hepatic metabolism). For these populations, preservative-free sterile water for injection is required. Benzyl alcohol allergy (rare) is another contraindication. Storage: room temperature (15-30°C), protect from freezing.

Batch/lot numbers encode manufacturing information: typical formats include production date codes, sequential numbers, facility identifiers, and product codes. Traceability: batch numbers link the finished product to: raw material lots (amino acids, excipients, solvents), in-process records (synthesis, purification, formulation parameters), quality control test results (COA), equipment used, personnel involved, and environmental monitoring data during manufacturing. Regulatory requirements: batch production records must be retained for at least 1 year beyond product expiry date (or longer per local requirements). In case of quality issues: the batch number enables identification and recall of all units from the affected production run. Serialisation (unit-level unique identifiers) provides even more granular traceability under FDA DSCSA and EU FMD requirements, enabling tracking of individual product units through the supply chain.

Cold chain requirements for peptide drugs: storage (2-8°C for most refrigerated products, -20°C for some frozen products, room temperature ≤25°C for some stable formulations), shipping (validated insulated packaging with phase-change materials or active temperature control systems), monitoring (data loggers recording temperature throughout transit — min/max and continuous recording; excursion documentation), and handling (receiving procedures verifying temperature upon arrival, proper pharmacy/hospital storage, patient-level storage guidance). Cold chain failures can cause: peptide degradation (potency loss, increased impurities), aggregation (potentially immunogenic), physical changes (precipitates, colour change), and complete product loss. Some peptide products have room temperature stability windows (e.g. semaglutide pens can be stored at room temperature for up to 6 weeks after first use) — these convenience features are established through stability testing. Cold chain logistics significantly impact product distribution costs and global accessibility.

CCI testing ensures the container-closure system maintains a microbial and physical barrier throughout shelf life. Methods: deterministic (providing quantitative measurement — helium leak testing, high-voltage leak detection, headspace analysis, vacuum decay) and probabilistic (based on microbial challenge — dye immersion/ingress, microbial immersion). USP <1207> provides guidance. For peptide drug products, CCI is critical because: parenteral products must remain sterile, peptides can be degraded by oxygen (Met oxidation, Trp degradation) requiring inert headspace, and moisture ingress can destabilise lyophilised products. Vial systems: Type I borosilicate glass vials with bromobutyl rubber stoppers and aluminium flip-off seals. Pre-filled syringe systems: glass barrel, elastomeric plunger stopper, rigid needle shield. Pen cartridge systems: glass barrel, bromobutyl rubber disc seal, aluminium crimp. Each system requires CCI validation specific to the product and process.

Common peptide degradation pathways: (1) Oxidation — Met oxidation to Met sulphoxide (most common, catalysed by trace metals and peroxides; reversible with reducing agents), Trp oxidation to N-formylkynurenine (irreversible), His oxidation, Cys oxidation. (2) Deamidation — Asn→Asp/isoAsp (rate depends on n+1 residue; Asn-Gly is fastest, t1/2 days-weeks; follows succinimide intermediate), Gln→Glu (much slower). (3) Hydrolysis — peptide bond cleavage, particularly at Asp-Pro sites (acid-catalysed). (4) Disulphide exchange — scrambling of disulphide bonds, producing misfolded isomers. (5) Aggregation — non-covalent (hydrophobic) and covalent (disulphide-mediated) association forming dimers, oligomers, and higher-order aggregates. Each pathway has characteristic analytical signatures: oxidation products detected by MS (+16 Da), deamidation products by MS (+1 Da) and charge variants by ion-exchange chromatography, and aggregation by size-exclusion chromatography (SEC).

ESI process: peptide solution flows through a capillary at high voltage (2-5 kV) → charged droplets form at the capillary tip (Taylor cone) → solvent evaporation in heated desolvation gas → repeated droplet fission (Coulomb explosion) → fully desolvated multiply charged peptide ions. Key advantage: multiply charged ions ([M+nH]n+) bring large peptides into the m/z range of standard mass analysers. For a 4 kDa peptide with 4 charges: m/z = 1001. Mass analysers: quadrupole (unit mass resolution, good for quantification), time-of-flight (high resolution, high mass accuracy), Orbitrap (ultra-high resolution, <1 ppm mass accuracy), and ion trap (MSn capability for structural characterisation). LC-ESI-MS/MS is the workhorse of pharmaceutical peptide analysis: characterising sequences, detecting modifications, quantifying impurities, and measuring peptide concentrations in biological matrices (pharmacokinetic studies).

Bacterial endotoxins (lipopolysaccharides, LPS) are the primary pyrogen concern for parenteral peptide products. LPS consists of: lipid A (the toxic component, embedded in the bacterial outer membrane), core polysaccharide, and O-antigen. Even nanogram quantities can cause fever, hypotension, and potentially fatal septic shock. LAL testing methods: gel-clot (qualitative — detects above/below a specified limit), turbidimetric (quantitative — measures turbidity increase from LAL clotting reaction), and chromogenic (quantitative — measures colour change from chromogenic substrate cleavage). Recombinant Factor C (rFC) assay is a newer alternative that avoids harvesting horseshoe crab blood. Endotoxin limits (USP/EP): for IV drugs, generally ≤5 EU/kg body weight/hour; for intrathecal drugs, ≤0.2 EU/kg. Depyrogenation of manufacturing equipment uses dry heat (≥250°C for ≥30 min) or chemical treatment.

Excipient categories for peptide formulations: (1) Stabilisers/lyoprotectants: sugars (sucrose, trehalose, mannitol — protect peptide structure during lyophilisation by hydrogen bonding to replace water), amino acids (glycine, arginine — stabilise against aggregation), surfactants (polysorbate 20/80 — prevent surface adsorption and aggregation). (2) Buffers: phosphate, citrate, histidine (maintain pH within stability range, typically pH 4-8 for peptides). (3) Tonicity agents: sodium chloride, mannitol (making solutions isotonic ~290 mOsm for injection comfort). (4) Preservatives: phenol, metacresol, benzyl alcohol (for multi-dose formulations — essential for preventing microbial growth after first use). (5) Solubilisers: propylene glycol, cyclodextrins (improving dissolution of hydrophobic peptides). Excipient selection for peptide formulations is critical because peptides are sensitive to pH, ionic strength, surface adsorption, oxidation, and aggregation.

Fmoc (9-fluorenylmethyloxycarbonyl) SPPS displaced the older Boc (tert-butyloxycarbonyl) strategy because: Fmoc removal uses mild base (piperidine/DMF) rather than strong acid (TFA for Boc), enabling orthogonal protection strategies; Fmoc cleavage can be monitored by UV absorbance (dibenzofulvene has strong UV absorption at 301nm, allowing real-time coupling efficiency monitoring); and acid-labile side chain protections are stable during Fmoc removal. Standard Fmoc amino acid side chain protections: Trt (trityl) for Cys, His, Asn, Gln; tBu (tert-butyl) for Ser, Thr, Tyr, Asp, Glu; Boc for Lys, Trp; Pbf for Arg. All side chain protections are removed simultaneously during TFA cleavage from resin. Difficult sequences (aggregation-prone regions, repeated amino acids) may require: pseudoproline dipeptide insertions, backbone protecting groups (Dmb, Hmb), or microwave-assisted synthesis to improve coupling efficiency.

Formulation development for peptide drugs follows ICH Q8 quality by design (QbD) principles: define target product profile (TPP) → identify critical quality attributes (CQAs: purity, potency, aggregation, particulates) → design formulation to achieve CQAs using design of experiments (DoE) and risk assessment. Key formulation decisions: liquid vs lyophilised (liquid is more convenient but peptides are often less stable in solution — liquid formulations require careful excipient selection; lyophilised products require reconstitution but offer better long-term stability), single-dose vs multi-dose (multi-dose requires preservative — preservative compatibility with peptide must be verified), and device selection (vial/syringe vs pen vs auto-injector — affects formulation volume, concentration, and viscosity requirements). Semaglutide example: Ozempic/Wegovy are multi-dose pen formulations containing semaglutide with disodium phosphate dihydrate, propylene glycol, and phenol (preservative).

HPLC system components: solvent delivery pump (generating pressures up to 400-600 bar), injector (introducing sample onto column), column (typically C18 reversed-phase, 4.6mm × 150-250mm with 3-5μm particles for analytical; 21-50mm × 150-250mm for preparative), detector (UV at 214nm for peptide bond absorption, 280nm for aromatic amino acids; or mass spectrometer for identification), and data system. Method parameters for peptide analysis: mobile phase A (water + 0.1% TFA or formic acid), mobile phase B (acetonitrile + 0.1% TFA or formic acid), gradient elution (typically 1%B/min linear gradient), flow rate (1mL/min analytical, 10-50mL/min preparative), and column temperature (typically 25-60°C). Ultra-HPLC (UHPLC) systems use sub-2μm particles and higher pressures for faster, higher-resolution separations. Method validation follows ICH Q2(R1): specificity, linearity, accuracy, precision, range, detection/quantification limits, and robustness.

Identity testing must be specific enough to distinguish the target peptide from closely related sequences. Methods: mass spectrometry (confirming molecular weight matches theoretical — primary identity method), amino acid analysis (hydrolysing the peptide and quantifying constituent amino acids — confirms overall composition but not sequence order), peptide mapping (enzymatic digest + LC-MS — confirms sequence coverage), HPLC retention time (comparing to authenticated reference standard — confirms chromatographic identity), and infrared spectroscopy (fingerprint comparison to reference spectrum). For quality control, at least two orthogonal identity methods are typically required. For peptide drugs with post-translational modifications (glycosylation, PEGylation), identity testing must also confirm the modification. Biosimilar identity testing requires extensive analytical comparison demonstrating high similarity to the reference product across multiple structural attributes.

ICH Q3A (drug substance) and Q3B (drug product) establish thresholds: reporting threshold (above which impurities must be reported in the specification — typically 0.05-0.1%), identification threshold (above which impurities must be structurally identified — typically 0.1-0.5% depending on daily dose), and qualification threshold (above which impurities must be toxicologically qualified — typically 0.15-1.0% depending on daily dose). For synthetic peptides, process-related impurities include: deletion peptides, truncated sequences, deprotection failures, racemised amino acids, aggregates, and residual reagents/solvents. Degradation-related impurities include: oxidation products (Met sulphoxide, Trp oxidation), deamidation products (Asp/isoAsp from Asn, Glu from Gln), hydrolysis products (cleavage fragments), and aggregation products. Forced degradation studies (ICH Q1A) — exposing the product to acid, base, oxidation, heat, light, and humidity — identify potential degradation pathways and validate the stability-indicating capability of analytical methods.

LAL is prepared from the blood cells (amebocytes) of horseshoe crabs (Limulus polyphemus, Atlantic species; Tachypleus tridentatus, Asian species). Amebocytes contain a clotting cascade (Factor C → Factor B → proclotting enzyme → clotting enzyme) that is activated by endotoxin binding to Factor C. This cascade produces a clot (gel-clot method) or cleaves chromogenic/fluorogenic substrates (quantitative methods). Sensitivity: LAL can detect endotoxin at concentrations as low as 0.001 EU/mL (approximately 0.1 pg/mL LPS). Interference testing: sample-specific validation is required because peptides, formulation components, or pH may inhibit or enhance the LAL reaction — maximum valid dilution (MVD) calculations determine the appropriate sample dilution. Conservation concerns about horseshoe crab harvesting have driven development of recombinant alternatives (rFC assay), now accepted by EP and under evaluation by USP/FDA for routine use.

In liquid-phase (solution-phase) synthesis, coupling and deprotection reactions occur in solution rather than on a solid support. Advantages: easier scale-up (no resin loading limitations), intermediate purification at each step is possible (allowing correction of errors), and no resin cleavage step needed. Disadvantages: requires purification after each step (time-consuming), excess reagent removal is more complex, and the approach is less amenable to automation. Solution-phase synthesis is used commercially for: very short peptides (2-5 amino acids) where SPPS overhead is unnecessary, large-scale production where resin costs become prohibitive, and convergent synthesis strategies where pre-formed peptide fragments are coupled in solution. Hybrid approaches combine SPPS for fragment preparation with solution-phase fragment condensation for assembling larger peptides.

Lyophilisation process steps: (1) formulation (peptide dissolved with excipients in water at target concentration/pH), (2) fill (aseptic filling into vials — critical step under ISO 5 cleanroom conditions), (3) freezing (controlled cooling to -40 to -60°C — cooling rate affects ice crystal size and cake morphology; annealing steps may be included to optimise crystal structure), (4) primary drying (sublimation — chamber pressure reduced to 50-200 mTorr, shelf temperature raised to -20 to -10°C; ice sublimes directly to vapour; duration 24-72 hours for typical peptide products), (5) secondary drying (desorption — shelf temperature raised to +20 to +40°C to remove residual unfrozen water; target <1-2% residual moisture), (6) stoppering (under controlled atmosphere, typically nitrogen), and (7) capping. Process parameters (shelf temperature, chamber pressure, ramp rates) must be optimised for each formulation. Cake appearance (elegant, uniform cake vs collapse, shrinkage, or meltback) is an important quality indicator.

During lyophilisation, water removal can denature peptides by: removing the hydrogen-bonding water shell (hydration layer) that stabilises native conformation, concentrating solutes (increasing ionic strength and changing pH), and subjecting the peptide to ice crystal formation stress. Lyoprotectants counteract these stresses through: water replacement hypothesis (disaccharides like sucrose and trehalose form hydrogen bonds with the peptide surface, replacing the stabilising water shell) and vitrification hypothesis (lyoprotectants form a glassy matrix that physically immobilises the peptide, preventing conformational changes). Optimal lyoprotectant:peptide ratios are typically 100:1 to 500:1 (w/w). The glass transition temperature (Tg) of the lyophilised cake must remain above storage temperature — if Tg is exceeded during storage, the glassy matrix softens and the peptide can degrade. Sucrose (Tg ~75°C) and trehalose (Tg ~115°C) are preferred over mannitol for amorphous glass formation.

MALDI process: peptide sample mixed with UV-absorbing matrix (alpha-cyano-4-hydroxycinnamic acid — CHCA — is standard for peptides) → co-crystallised on a metal target plate → pulsed UV laser (337nm nitrogen laser or 355nm Nd:YAG) → matrix absorbs energy and vaporises, carrying analyte into gas phase as singly charged ions → ions accelerated through electric field → flight time through field-free drift tube is proportional to √(m/z) → detector measures arrival time. Advantages: rapid analysis (<1 minute per sample), tolerant of salts and buffers, produces primarily singly charged ions (simplifying spectra), and suitable for high-throughput screening. For peptide QC: measured mass is compared to theoretical mass calculated from the sequence. Mass accuracy of ±0.1 Da is typical for modern MALDI-TOF instruments. MALDI imaging MS can map peptide distribution in tissue sections — an emerging research tool.

MS for peptide analysis: MALDI-TOF (matrix-assisted laser desorption/ionisation time-of-flight) — sample co-crystallised with matrix, laser pulse desorbs/ionises analyte, ions separated by time-of-flight; provides molecular weight with accuracy of ±0.01% (±1 Da for a 10 kDa peptide). ESI-MS (electrospray ionisation) — sample in solution, high voltage creates charged droplets, solvent evaporation produces multiply charged ions; enables direct coupling to HPLC (LC-MS). Tandem MS (MS/MS): selected ions are fragmented by collision-induced dissociation (CID) → fragment ion analysis provides sequence information. Common fragmentation nomenclature: b-ions (N-terminal fragments), y-ions (C-terminal fragments). LC-MS/MS is the gold standard for peptide identification, de novo sequencing, post-translational modification analysis, and impurity characterisation in pharmaceutical quality control.

USP <788> / Ph. Eur. 2.9.19 methods: light obscuration (automated particle counter — quantitative, measures particles ≥10μm and ≥25μm in injectable solutions) and membrane microscopy (visual counting on membrane filter — confirmatory method and primary method for low-volume products). Specifications for small-volume injectables (≤100mL): ≤6000 particles ≥10μm per container, ≤600 particles ≥25μm per container. Visible particle inspection: 100% of containers visually inspected against black and white backgrounds under standardised lighting. For peptide drugs, particulate sources include: protein aggregation (the most peptide-specific concern — aggregated peptides form sub-visible and visible particles), glass delamination (from vial inner surface), silicone oil droplets (from syringe lubrication), fibre contamination (from environment), and precipitated excipients. Aggregated peptide particles are particularly concerning because they can be immunogenic.

Peptide mapping (fingerprinting) procedure: (1) denature and reduce the peptide/protein (unfolding and breaking disulphide bonds with DTT or TCEP under denaturing conditions), (2) alkylate free cysteines (preventing disulphide re-formation with iodoacetamide or N-ethylmaleimide), (3) enzymatic digestion (trypsin is standard — cleaves after Arg and Lys with high specificity; Glu-C, Asp-N, chymotrypsin provide complementary cleavage for complete sequence coverage), (4) LC-MS analysis (RP-HPLC separation coupled to high-resolution MS), and (5) data analysis (matching observed fragment masses to theoretical digest, confirming sequence coverage, identifying modifications). Peptide mapping provides: sequence confirmation (>95% coverage expected), post-translational modification identification (oxidation, deamidation, glycosylation sites), disulphide bond assignment, and detection of sequence variants or modifications. It is the most informative single analytical method for peptide/protein characterisation and is essential for biosimilar comparability assessment.

Purity specifications depend on application: pharmaceutical grade (>98-99%, with individual specified impurities <0.5% and total impurities <2%), clinical trial material (>95-98%), research grade (>95%), and custom synthesis (variable, 70-98%). Impurity types: deletion peptides (missing one amino acid — caused by incomplete coupling), truncated sequences (synthesis terminated prematurely), insertion peptides (double coupling of an amino acid), oxidation products (Met→Met(O), Trp→oxyindole), deamidation products (Asn→Asp/isoAsp, Gln→Glu), racemisation (L→D at activated positions), and TFA/acetonitrile residues from purification. ICH Q3A/B impurity guidelines define: reporting threshold (above which impurities must be identified), identification threshold (requiring structural characterisation), and qualification threshold (requiring toxicological evaluation). For biotechnology products, ICH Q6B provides specific quality attribute guidance.

Potency assays for peptide drugs: (1) bioassays — cell-based functional assays measuring the biological response (e.g. GLP-1R activation assay using cAMP readout for GLP-1 RAs, growth hormone bioassay using Nb2 cell proliferation for somatropin) — most physiologically relevant but higher variability and longer turnaround time; (2) receptor binding assays — competitive binding to the target receptor using radiolabelled or fluorescent ligand — measures binding activity but not downstream signalling; (3) enzyme activity assays — for enzyme-based drugs (e.g. proteasome inhibition assay for bortezomib). Potency is expressed relative to a reference standard in international units (IU) or as percentage of reference. Assay validation parameters (per ICH Q2): specificity, linearity (dose-response range), accuracy, precision (repeatability and intermediate precision), and robustness. For biological products, USP requires lot-by-lot potency testing.

FDA process validation guidance (2011) defines three stages: Stage 1 (Process Design — developing understanding of the process through DOE, scale-down studies, and defining critical process parameters and their acceptable ranges), Stage 2 (Process Qualification — confirming the process performs as expected at commercial scale, typically 3 consecutive successful validation batches meeting all specifications), Stage 3 (Continued Process Verification — ongoing monitoring ensuring the process remains in a validated state during routine production). For SPPS-based peptide production, critical process parameters include: coupling reagent concentrations, reaction times, temperatures, washing volumes, cleavage conditions (TFA concentration, time, temperature, scavenger ratios), and purification parameters (HPLC gradient, loading, flow rate). Process validation must demonstrate that: each batch meets the defined quality attributes, batch-to-batch variability is within acceptable limits, and the process is reproducible across operators, equipment, and raw material lots.

QA encompasses the entire quality management system (QMS) per ICH Q10: pharmaceutical quality system elements include: management commitment (quality policy, resource allocation), process performance and product quality monitoring (statistical process control, trending), corrective and preventive action (CAPA — investigating root causes of deviations and implementing systemic improvements), change management (controlling changes to processes, equipment, and materials through formal review and approval), and management review (periodic assessment of QMS effectiveness). QA activities specific to peptide manufacturing include: supplier qualification (ensuring amino acid and excipient suppliers meet quality standards), facility qualification (cleanroom environmental monitoring — viable and non-viable particle counts, temperature, humidity), equipment qualification (IQ/OQ/PQ for synthesisers, HPLC systems, lyophilisers), and annual product reviews (comprehensive assessment of all batches produced in a year, identifying trends).

QC testing for peptide drugs: identity (confirmed by MS and/or AA analysis — ensuring the correct peptide is in the vial), purity (RP-HPLC — total purity and individual impurity levels), potency (bioassay or binding assay — confirming biological activity), sterility (USP <71> — 14-day incubation), endotoxin (LAL test — ensuring below pyrogenic threshold), water content (Karl Fischer titration — critical for lyophilised products), pH (for liquid formulations and reconstituted solutions), particulate matter (USP <788> — visible and sub-visible particles), container closure integrity (ensuring seal maintains sterility), appearance (visual inspection — colour, clarity, cake morphology), and peptide content (quantifying active ingredient per vial/dose). QC laboratories operate under cGMP with validated analytical methods, calibrated instruments, and qualified personnel. Out-of-specification (OOS) results trigger formal investigations per 21 CFR 211.192.

Reconstitution technique affects product quality: liquid (bacteriostatic water or sterile water for injection) should be directed gently down the inner vial wall, not squirted directly onto the lyophilised cake (which can cause foaming and peptide denaturation at the air-liquid interface). Gentle swirling is acceptable but vigorous shaking should be avoided (mechanical stress can cause aggregation). Reconstitution time varies: well-formulated peptide cakes typically dissolve in 1-5 minutes. Visual inspection after reconstitution should confirm: complete dissolution (no visible particles), appropriate colour (typically colourless to slightly yellow for most peptides), and appropriate clarity (clear to slightly opalescent). Reconstituted peptide stability (in-use shelf-life): with bacteriostatic water — typically up to 28 days refrigerated; with sterile water — use immediately or within 24 hours. Patient education on proper reconstitution technique is critical for self-administered lyophilised peptide products.

Reference standard hierarchy: primary reference standard (USP Reference Standard, Ph. Eur. Chemical Reference Substance, WHO International Standard — independently characterised by compendial organisations using multiple orthogonal methods), and working/secondary reference standard (qualified against primary standard — used for routine QC to conserve limited primary standard material). Qualification of working standards requires: identity confirmation (MS, AAA), purity assessment (HPLC), potency comparison to primary standard (bioassay or binding assay), and assignment of correction factor if purity differs from primary. Reference standard storage: typically -20°C or -80°C in sealed, desiccated vials. Reconstitution/aliquoting procedures must be defined to ensure stability. For peptide drugs, reference standard characterisation includes: full structural confirmation (sequence, modifications, disulphide bonds), purity/impurity profile, biological activity, and stability data.

Release testing represents the final quality gate before product distribution. The release specification set is defined in the regulatory filing (Module 3/CMC section of the CTD) and approved by regulatory authorities. Each test has: a validated analytical method (per ICH Q2), an acceptance criterion (specification limit), and a reference standard for comparison. Release testing must be completed for every batch before it is released for distribution — partial testing or skip-lot testing is generally not acceptable for parenteral products. Batch release authority rests with the Qualified Person (QP) in the EU or the quality unit head in the US. The QP/quality unit reviews: all batch production records, in-process control results, release test results, deviation investigations, and compliance with the marketing authorisation before authorising release. Any OOS result must be fully investigated before a release decision is made.

ICH Q3C classifies solvents: Class 1 (should be avoided — carcinogens/environmental hazards: benzene, carbon tetrachloride), Class 2 (should be limited — non-genotoxic toxicity: DMF limit 880ppm, DCM limit 600ppm, methanol limit 3000ppm, acetonitrile limit 410ppm, TFA — not classified but typically limited to <0.1%), Class 3 (low toxic potential, limits ≥5000ppm: acetone, ethanol, ethyl acetate). Testing by headspace gas chromatography (HS-GC) — volatile solvents partition into the headspace above a heated sample and are separated/quantified by GC-FID or GC-MS. For SPPS-derived peptides, typical residual solvents include: DMF, DCM (from synthesis), acetonitrile, TFA (from HPLC purification), and diethyl ether (from precipitation). Residual solvent specifications are defined in the drug substance specification and verified in release testing.

RP-HPLC uses a non-polar stationary phase (C18, C8, C4 bonded silica — C18 is most common for peptides <5 kDa, C4 for larger peptides/proteins where C18 binding may be too strong) and a polar mobile phase. Peptides bind to the non-polar stationary phase via hydrophobic interactions; increasing organic solvent (acetonitrile) concentration during gradient elution disrupts these interactions, eluting peptides in order of increasing hydrophobicity. For peptide purity analysis: the area percentage of the target peptide peak relative to total peak area gives the purity value. Related impurities (deletion peptides, truncated sequences, oxidised forms) typically elute close to the target peak, requiring sufficient resolution. Ion-pair reagents (TFA, formic acid) protonate basic residues and pair with acidic residues, improving peak shape and resolution. Peptide retention time is predictable from amino acid composition using hydrophobicity scales.

Shelf life is determined from real-time stability data: the point at which the lower 95% confidence limit of the stability parameter (purity, potency) crosses the specification limit. ICH Q1E provides statistical methods for shelf-life estimation from stability data. Typical shelf lives: lyophilised peptide products (18-36 months at 2-8°C), liquid peptide formulations (12-24 months at 2-8°C), and some room-temperature-stable formulations (up to 24 months at 25°C). After first use (multi-dose products): semaglutide pen 6 weeks at room temperature or refrigerated; reconstituted lyophilised peptides 28 days with BWFI at 2-8°C. Expired peptide products should not be used — degradation products may be present that reduce efficacy or potentially cause adverse effects. Pharmaceutical stability programmes continue testing beyond the established shelf life to generate supporting data for potential shelf-life extensions.

SPPS workflow: (1) resin selection (Wang resin for C-terminal acids, Rink amide resin for C-terminal amides — resin loading determines scale), (2) first amino acid coupling (loading onto resin via ester or amide bond), (3) iterative cycles of deprotection (removing Fmoc group with 20% piperidine in DMF, ~5-20 minutes) → washing → coupling (activating the next Fmoc-amino acid with coupling reagents such as HBTU/HOBt or HATU/HOAt and adding to the growing chain, ~30-60 minutes) → washing → monitoring (Kaiser test or TNBS test for free amines to confirm coupling completion), (4) final deprotection, (5) cleavage from resin (TFA cocktail — typically 95% TFA with scavengers such as triisopropylsilane and water — removes side chain protecting groups simultaneously), (6) precipitation and crude peptide isolation, (7) purification by preparative RP-HPLC, (8) lyophilisation. Automated peptide synthesisers perform steps 2-3 with minimal human intervention. SPPS is practical for peptides up to approximately 50 amino acids; longer sequences may require segment condensation (native chemical ligation or fragment coupling strategies).

ICH Q1A(R2) stability conditions: long-term (25°C±2/60%RH±5% — primary shelf-life data), intermediate (30°C±2/65%RH±5% — if significant change at long-term), accelerated (40°C±2/75%RH±5% — stress testing, 6 months; if significant change at 3 months, long-term data required), and photostability (ICH Q1B — confirming light sensitivity and justifying light-protection measures). Testing intervals: long-term — 0, 3, 6, 9, 12, 18, 24, 36 months (annually thereafter until expiry); accelerated — 0, 3, 6 months. Parameters tested: appearance, purity/impurities (HPLC), potency, pH, water content, sterility (at initial and end), endotoxin, and product-specific tests. For lyophilised peptides, reconstituted stability (stability after dissolving in solvent) must also be established — this determines the in-use shelf-life after preparation. Peptide-specific degradation pathways monitored: oxidation (Met, Trp, Cys), deamidation (Asn, Gln), aggregation, and hydrolysis.

SWFI (USP) is purified water that has been sterilised by autoclaving or membrane filtration, packaged in single-use containers, and contains no preservatives, antimicrobials, or added substances. Specifications: pH 5.0-7.0, conductivity ≤1.3 μS/cm at 25°C, TOC (total organic carbon) ≤500 ppb, endotoxin <0.25 EU/mL. Because it lacks preservatives, reconstituted peptide solutions using SWFI should be used immediately or within 24 hours (refrigerated) — there is no antimicrobial protection against contamination during withdrawal. SWFI is required for: neonatal preparations, single-dose immediate-use products, and patients with benzyl alcohol sensitivity. For research peptide reconstitution, the choice between BWFI and SWFI depends on whether multiple withdrawals from a single reconstituted vial are planned.

USP <71>/Ph. Eur. 2.6.1 sterility test: membrane filtration (filter sample through 0.45μm membrane → transfer membrane to growth medium → incubate) or direct inoculation (add sample directly to growth media). Media: fluid thioglycollate medium (FTM, 30-35°C — supports anaerobic and aerobic bacteria) and soybean-casein digest medium (SCDM/TSB, 20-25°C — supports aerobic bacteria and fungi). Incubation period: 14 days minimum. Any turbidity indicates test failure → investigation required (is it true contamination or false positive?). Limitations: sterility testing is destructive (samples cannot be retested), has limited statistical power (testing a small sample from a large batch), and cannot detect very low levels of contamination. Parametric release (releasing batches based on validated sterilisation process parameters rather than sterility testing of individual batches) is accepted for terminally sterilised products but not for aseptically processed peptide products.

Terminal sterilisation methods: autoclaving (saturated steam at 121°C for ≥15 min — the gold standard, providing sterility assurance level SAL of 10^-6), dry heat (≥160°C for ≥2 hours — also depyrogenates), gamma irradiation (25-50 kGy from cobalt-60 or caesium-137), electron beam irradiation, and chemical sterilisation (ethylene oxide — primarily for devices). For peptide drugs, terminal sterilisation is rarely feasible because: most peptides denature above 50-60°C (excluding autoclaving and dry heat), gamma irradiation causes peptide bond cleavage, oxidation, and deamidation (degrading the product), and chemical sterilants may react with peptide functional groups. Exception: some small, robust peptide solutions can tolerate F0-based sterilisation cycles (lower temperature, longer time) if validated to achieve SAL 10^-6. Sterile filtration followed by aseptic processing remains the standard approach for most peptide injectable products.

Karl Fischer (KF) titration is the reference method for water determination in pharmaceuticals. The reaction: I2 + SO2 + 3 pyridine + CH3OH + H2O → 2 pyridinium hydroiodide + pyridinium methylsulphate (one mole of I2 reacts with one mole of water). Coulometric KF (generating I2 electrochemically — suitable for low water content, 1ppm-5%) is used for lyophilised peptide products; volumetric KF (adding I2 from titrant solution — suitable for higher water content) for other applications. Residual moisture in lyophilised peptides directly affects stability — excessive water (>3-5%) accelerates degradation through hydrolysis, deamidation, and aggregation. Target residual moisture is typically 0.5-2.0% for optimal stability. The relationship between water content and glass transition temperature (Tg) is critical — even small increases in moisture can significantly depress Tg, destabilising the glassy matrix.